Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patientsJournal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.1000-1000 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2013.31.15_suppl.1000Full text available |
|
2 |
Material Type: Article
|
13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemiaJournal of clinical oncology, 1985-04, Vol.3 (4), p.473-476 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.1985.3.4.473 ;PMID: 3856630Digital Resources/Online E-Resources |
|
3 |
Material Type: Article
|
17-year incidence trends of anal squamous cell carcinomaJournal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4058-4058 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2020.38.15_suppl.4058Full text available |
|
4 |
Material Type: Article
|
177 Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community settingJournal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16249-e16249 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.16_suppl.e16249Digital Resources/Online E-Resources |
|
5 |
Material Type: Article
|
20-year incidence trends of anal squamous cell carcinomaJournal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15503-e15503 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.16_suppl.e15503Digital Resources/Online E-Resources |
|
6 |
Material Type: Article
|
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of clinical oncology, 2006-07, Vol.24 (19), p.3187-3205 [Peer Reviewed Journal]2006 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2006.06.4451 ;PMID: 16682719Full text available |
|
7 |
Material Type: Article
|
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA506-LBA506 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.17_suppl.LBA506Digital Resources/Online E-Resources |
|
8 |
Material Type: Article
|
30-day readmission among gastrointestinal cancer patients in TexasJournal of clinical oncology, 2013-11, Vol.31 (31_suppl), p.121-121 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2013.31.31_suppl.121Full text available |
|
9 |
Material Type: Article
|
30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa)Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16597-e16597 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2019.37.15_suppl.e16597Full text available |
|
10 |
Material Type: Article
|
300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real?Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e17535-e17535 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2009.27.15_suppl.e17535Full text available |
|
11 |
Material Type: Article
|
5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health careJournal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.39-39 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2020.38.6_suppl.39Full text available |
|
12 |
Material Type: Article
|
5 x 5 Gy and consolidation chemotherapy vs long-course preoperative chemoradiation for locally advanced rectal cancer: An interim analysis of a randomized phase III studyJournal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15006-e15006 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2017.35.15_suppl.e15006Full text available |
|
13 |
Material Type: Article
|
5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II StudyJournal of clinical oncology, 1999-04, Vol.17 (4), p.1118-1126 [Peer Reviewed Journal]1999 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.1999.17.4.1118 ;PMID: 10561169Digital Resources/Online E-Resources |
|
14 |
Material Type: Article
|
5-year survival following radiotherapy in anal cancer audit in a single centerJournal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e15070-e15070 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2019.37.15_suppl.e15070Full text available |
|
15 |
Material Type: Article
|
5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: Phase II study resultsJournal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3599-3599 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2006.24.18_suppl.3599Full text available |
|
16 |
Material Type: Article
|
89 Zirconium-labelled girentuximab ( 89 Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinomaJournal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4609-TPS4609 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2022.40.16_suppl.TPS4609Full text available |
|
17 |
Material Type: Article
|
89 Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IXJournal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS738-TPS738 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.6_suppl.TPS738Full text available |
|
18 |
Material Type: Article
|
90 Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent TrialJournal of clinical oncology, 2013-06, Vol.31 (16), p.1977-1983 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.6400Full text available |
|
19 |
Material Type: Article
|
90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent TrialJournal of clinical oncology, 2013-06, Vol.31 (16), p.1977-1983 [Peer Reviewed Journal]2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.6400 ;PMID: 23547079Full text available |
|
20 |
Material Type: Article
|
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trialJournal of clinical oncology, 2013-06, Vol.31 (16), p.1977 [Peer Reviewed Journal]EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.6400 ;PMID: 23547079Full text available |